Citations

Clear

280 citation(s) found for "Connolly, RM".

Ventricular Morphology and Atrioventricular Valve Regurgitation in Adults Post-Fontan: Associations With Exercise Hemodynamics
Van den Eynde, Jef , Van De Bruaene, Alexander , Egbe, Alexander C , Van Belle, Hannah , Charles Jain, C , Borlaug, Barry A , Nishimura, Rick , Connolly, Heidi M , Dearani, Joseph A. , d'Udekem, Yves , Budts, Werner , Eleid, Mackram F , Miranda, William R

Mayo Clinic

Circulation: Cardiovascular Interventions | November 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circinterventions.126.017083 | PMID 43046954 Get It

BACKGROUND: Right ventricular (RV) dominance and atrioventricular valve regurgitation (AVVR) are associated with adverse outcomes post-Fontan palliation, but their underlying hemodynamic correlates, particularly during exercise, remain incompletely characterized. METHODS: In this cross-sectional cohort, exercise hemodynamics by ventricular morphology and AVVR severity were assessed invasively (supine exercise catheterization) in 108 individuals and semi-invasively (semisupine exercise with echocardiography and peripheral venous pressure) in 108. RESULTS: Age of the invasive cohort was 32.1 (25.6–37.2) years; 41 had RV dominance, 19 had moderate or severe AVVR, and 16 had both. Resting and peak mean pulmonary artery pressure and pulmonary artery wedge pressure were similar across ventricular morphologies and AVVR severity. However, RV dominance was associated with lower systemic (systemic blood flow, 67% [22–93] versus 86% [63–105] predicted; P =0.006) and pulmonary (pulmonary blood flow, 57% [33–75] versus 72% [61–89] predicted; P <0.001) cardiac output responses to exercise and steeper Δpulmonary artery pressure/Δpulmonary blood flow, (4.3 [2.6–10.6] versus 3.0 [1.7–4.8] mm Hg/L per minute; P =0.004). Patients with moderate or severe AVVR showed a similar pattern, with lower systemic blood flow (64% [19–92] versus 77% [57–101], P =0.10) and pulmonary blood flow (57% [36–74] versus 70% [55–88] predicted, P =0.03) responses. Findings were replicated in the semi-invasive cohort, where RV dominance and moderate or severe AVVR were associated with lower peak systemic blood flow and higher Δperipheral venous pressure/Δ systemic blood flow, despite similar peak peripheral venous pressure. CONCLUSIONS: Resting and exertional pulmonary artery wedge pressure, pulmonary artery pressure, and peripheral venous pressure are unrelated to ventricular morphology and AVVR severity. Conversely, impaired flow augmentation and steeper pressure-flow relationships during exercise were associated with RV dominance and moderate or severe AVVR, emphasizing the role of dynamic provocation to unmask occult cardiovascular reserve limitations.
Heart failure therapy in congenitally corrected transposition of the great arteries: effect on right ventricular function and survival
Ahmed, Sara, Karara, Yehia , Rashwan, Rana , Miranda, William R. , Connolly, Heidi M. , Egbe, Alexander C.

Mayo Clinic

European Heart Journal | November 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurheartj/ehag854 | PMID 42981224 Get It

Abstract Background and Aims The aim of the study was to assess the effect of guideline-directed medical therapy (GDMT) on cardiac function, neurohormonal activation, and mortality in adults with congenitally corrected transposition of the great arteries (cc-TGA) presenting with systemic right ventricular (RV) systolic dysfunction. The study hypothesis was that GDMT use (assessed using the GDMT score) was associated with improved cardiac function (higher RV free wall strain [RVFWS]), less neurohormonal activation (lower N-terminal pro-B-type natriuretic peptide [NT-proBNP] levels), and lower mortality. Methods GDMT score, RVFWS, and NT-proBNP levels were assessed at baseline and 1-year follow-up. GDMT uptitration was assessed using ΔGDMT (GDMT at 1-year minus GDMT at baseline). Improvements in RV systolic function and neurohormonal activation were defined as a relative increase in RVFWS of &gt;20% and a relative decrease in NT-proBNP levels of &gt;20%, respectively. Results Of 213 patients (age 43 ± 15 years; 54% male), baseline GDMT score was 1.97 ± 1.27, and ΔGDMT score was 0.74 ± 0.39. Baseline RVFWS was −18 ± 5%; 25% had improved RV systolic function. Baseline NT-proBNP was 369 (142, 1004) pg/mL; 56% had improved neurohormonal activation. Higher baseline GDMT score and ΔGDMT score were associated with improvement in RV systolic function and neurohormonal activation. Overall, 34 (16%) patients died, and higher baseline GDMT score and ΔGDMT score were associated with a lower risk of mortality and of the composite adverse event endpoint (heart failure hospitalization, death, and heart transplantation). Clinical benefits of GDMT use were observed only in patients with moderate/severe RV systolic dysfunction, and not in patients with mild RV systolic dysfunction. Conclusions GDMT use was associated with improved outcomes in patients with moderate/severe RV systolic dysfunction.
Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma
Kassamali, Bina , Schoenfeld, Jonathan D., Sethi, Rosh, Bakst, R H, Barker, C. A., Bradford, Carol R., Carr, David R., Chandra, Sunandana , Connolly, Karen L., Demer, Addison M. , Doonan, Bently, Emerick, Kevin, Friedman, Ben J. , Gali, Linna L., Galloway, Thomas J., Geiger, Jessica L., Kohen, Laurie, Koyfman, Shlomo, Kumar, Shweta Sharat, Learned, Kim O. , Leitenberger, Justin J., Lilley, Elizabeth J. , Lukens, John N. , Medina, Theresa , Mitra, Devarati , Ozog, David, Pashtan, Itai, Pham, Nancy , Powers, Molly, Srivastava, Divya, Taylor, Charlotte S., Witek, Matthew E. , Wysong, Ashley, Zander, David, Silk, Ann W., Jambusaria-Pahlajani, Anokhi, Ruiz, Emily S., Chen, Michelle , Kumar, Shweta S. , Schoenfeld, Jonathan D. , Barker, Christopher A. , Bhatt, Alok A. , Bradford, Carol R. , Bunch, Paul M. , Carr, David R., Carucci, John A. , Chen, Michelle , Connolly, Karen , Doonan, Bently P. , Emerick, Kevin S. , Friedman, Ben J. , Galloway, Thomas J. , Guenette, Jeffrey P. , Kelly, Hillary R. , Khushalani, Nikhil I. , Kohen, Laurie Linden, Leitenberger, Justin J. , Medina, Theresa M. , Pashtan, Itai , Patel, Vishal Anil , Srivastava, Divya , Swiecicki, Paul Loren , Wysong, Ashley, Silk, Ann Willman , Jambusaria‐Pahlajani, Anokhi , Ruiz, Emily S.

Mayo Clinic

JAMA Dermatology | July 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamadermatol.2026.2163 | PMID 42418212 Get It

Importance There is no consensus on staging and surveillance imaging for cutaneous squamous cell carcinoma (CSCC). Although imaging has been shown to affect management, broad recommendations from the National Comprehensive Cancer Network have led to variability in clinical practice. Objective To develop multidisciplinary consensus recommendations on the use of staging and surveillance imaging of localized CSCC. Evidence Review A multidisciplinary expert panel across academic and clinical practice settings convened a Delphi consensus, with 3 iterative survey rounds from January to June 2025. Data were analyzed from February 2025 to January 2026. Eligibility defined by at least 1 to 2 CSCC publications during the previous 5 years, involvement in a relevant clinical trial, experience treating at least 3 patients monthly with CSCC, and/or 5 years or longer of clinical practice. Fifty-four experts were invited and 45 (83%) completed all 3 rounds and were included in the final analysis. Structured Delphi surveys evaluated clinical scenarios, imaging modalities, and surveillance strategies for CSCC. Consensus and near-consensus recommendations were generated, defined as 80% or greater and 70% to 79% agreement, respectively. Findings The 45 participants (21 female individuals [47%] and 24 male individuals [53%]; 14 Asian individuals [31%], 1 multiracial individual [2%], and 30 White individuals [67%]) consisted of dermatology (15 [33%]), medical oncology (7 [16%]), radiation oncology (9 [20%]), radiology (9 [20%]), surgery (3 [7%]), and otolaryngology specialists (2 [4%]). The Delphi panel recommended staging and surveillance for CSCCs with at least a 15% risk of metastasis. Consensus or near consensus was reached to recommend staging and surveillance imaging for tumors with a concern for metastasis, bone invasion, invasion beyond subcutaneous fat, large-caliber nerve invasion, or a diameter of 4 cm or larger or the combination of tumors with poorly differentiated histology and any of the following: diameter of 2 cm or larger, lymphovascular invasion and subcutaneous fat invasion, or lymphovascular invasion and small-caliber perineural invasion. Computed tomography imaging was the preferred modality for nodal staging (38 [84%]) and surveillance (35 [78%]). For surveillance duration, consensus was reached to provide imaging for at least 2 years, and near consensus was reached for at least 3 years. Conclusions and Relevance This study provides an expert consensus–based framework to standardize imaging in localized CSCC that may inform future guidelines.
Outcomes of liver resections for neuroendocrine tumor liver metastases in carcinoid heart disease
Ammann, M, Podrascanin, Vanja, Pereyra, David, Dong, Yawen , Connolly, Heidi M. , Schaff, Hartzell V., Warner, Susanne G, Truty, M., Kendrick, Michael L. , Smoot, Rory L., Nagorney, David M. , Ammann, Markus , Santol, Jonas , Dong, Yawen , Halfdanarson, Thorvardur R , Gudmundsdottir, Hallbera , Podrascanin, V. , Santol, Jonas , Pellikka, Patricia A. , Crestanello, Juan A. , Thiels, Cornelius A. , Warner, Susanne G. , Truty, Mark J. , Hálfdánarson, Þorvarður R. , Starlinger, Patrick

Mayo Clinic

Journal of Neuroendocrinology | July 1, 2026 | Volume: 38 | Issue: 7 | Pages: No page available

10.1111/jne.70226 | PMID 42379658 Get It

Abstract Carcinoid heart disease (CHD) is associated with advanced neuroendocrine tumor liver metastases (NETLM) and may preclude surgical cytoreduction. We assessed perioperative and long‐term outcomes of hepatectomy in patients with CHD. We retrospectively analyzed 311 patients undergoing cytoreductive hepatectomy for intestinal NETLM: non‐functional ( n = 163), carcinoid syndrome (CS) without CHD ( n = 110), and CHD ( n = 38), including patients undergoing pre‐hepatectomy valve replacement. CHD patients more frequently had >10 liver metastases (78%) and larger lesions (median 9.5 cm) and required major hepatectomy more often (58%). Major morbidity was higher in CHD (up to 47%), yet 90‐day mortality remained low (≤4%). Median overall survival after hepatectomy was comparable across groups (12.5 vs. 9.1 vs. 11.4 years; p = .19), including matched analyses. With optimal cardiac management, cytoreductive hepatectomy in CHD is feasible and provides long‐term survival comparable to patients without CHD.
A36-23 Asthma Care in Maryland: A Qualitative Study of Patient Perceived Barriers
Connolly, M, Molavi, C, Knott, C, Rank, M A, Rose, J J, McCoy, R, Rose, J J

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 22, 2026 | Volume: 212 | Issue: Supplement_2 | Pages: No page available

10.1093/ajrccm/aamag286.043 Get It

Abstract Rationale High rates of poor asthma control have resulted in over 8 million annual exacerbations. With the introduction of biologic agents, even patients with severe persistent asthma are often able to avoid emergency department (ED) use and hospitalization with appropriate preventive treatment. However, access to and utilization of guideline-recommended biologic agents has remained suboptimal. This interview-based study was designed to evaluate barriers hindering access to preventive treatments from the patient perspective. Methods Using electronic health records of a large state-wide healthcare system serving a diverse population, we identified adults with asthma who experienced at least one hospital admission or ED visit in 2025 for acute asthma exacerbation while being treated with a medium or high dose inhaled corticosteroid and at least one other controller therapy. Eligible individuals were contacted to offer participation in a semi-structured interview focused on patient perceived care access barriers. We aimed for 20-25 participants, guided by thematic saturation. All interviews were transcribed and analyzed using NVivo software. Results Twenty-one participants were interviewed, reporting barriers to asthma care across five thematic areas: cost, care availability, logistical barriers, medical literacy and preferences, and desire for rapidly effective treatment (Table 1). Participants reported high out of pocket costs resulting in skipping refills or routine clinical visits, with some participants reporting seeking care in ED or hospital settings due to unaffordable costs encountered through traditional outpatient care routes. Participants also reported not bringing symptoms to outpatient care providers’ attention due to their chronicity and the perception that these symptoms were “normal” over time.When discussing outpatient specialist access, participants highlighted barriers including long wait times, travel distance, referral restrictions, and clinic hours resulting in conflicts limiting scheduling opportunities. Many participants also reported feeling more comfortable with seeking care through inpatient or emergency care facilitates due to perceived faster response time of providers and more immediate effectiveness of treatments provided. Finally, participants reported limited understanding of treatment goals, anticipated disease and treatment course, and side effects associated with rescue treatments such as systemic steroids. Conclusions This qualitative study provides rich data on barriers to care experienced by patients with poorly controlled asthma. Our results highlight novel potential areas for intervention including target areas to clarify communication of symptom control goals and treatment expectations. Future research should explore the most effective ways to address these care barriers with the goal of improving access to preventative therapies among patients living with asthma. This abstract is funded by: University of Maryland Baltimore, Institute for Clinical & Translational Research (ICTR) [grant number UM1TR004926-02]
Development of a Core Outcome Domain Set for Facial Aging
Dirr, McKenzie A. , Ahmed, Areeba, Schlessinger, Daniel I., Lazaro-Camp, Vanessa, Smith, SJ, Gullapalli, Thanvi, Dragovic, Doroteja, Chang, Joycie, Zhang, Elizabeth, Alam, Murad, Group, Facial Aging Core Outcome Domain Set Study, Anvery, Noor , Kang, Bianca Y. , Wong, Clarissa, Iyengar, Sanjana, Yanes, Arianna F. , Cotseones, Jill, Ashchyan, Hovik J. , Patel, P. M., Sheikh, Umar A., Franklin, Matthew , Hanna, Courtney, Chiren, Sarah G., Schmitt, J, Furlan, Karina C., Alexiades, Macrene, Alhusayen, Raed, Alster, Tina S. , Beer, Kenneth, Bertucci, Vince , Bloom, Jason D. , Briceño, César A., Bucay, Vivian, Butterwick, Kimberly J., Hugues, Cartier, Casabona, Gabriela, Connolly, Karen , Cox, Sue Ellen , Darmanescu, Monica, Boulle, Koenraad De , Desai, Shraddha, Donofrio, Lisa, Dover, Jeffrey S., Draelos, Zoe, Eisen, Daniel B. , El-Domyati, Moetaz, El-Garem, Yehia, Fischer, John, Fitzgerald, Rebecca, GALADARI, Hassan, Gladstone, Hayes B., Goldman, Mitchel P., Goodman, Greg J., Hanke, C. William , Humphrey, Shannon, Ibrahim, Sherrif F., Jagdeo, Jared, Karen, Julie, Kauvar, Arielle, Ag, Kibbi, KIM, JENNY, Lacerda, D T D, Lask, G, Lopez, Grace M., Lupo, Mary P. , Mariwalla, Kavita , Matarasso, Seth, Mekokishvili, L, Narins, Rhoda S., Ogilvie, P, Orringer, Jeffrey S. , Osaki, Tammy H. , Ozog, David, Pacheco, Theresa, Polder, Kristel, Rossi, Anthony M, Sadick, Neil, Saedi, Nazanin, Schlessinger, Joel, Sharad, Jaishree , Shenoy, SuchitraM, Sinclair, Rd, Solish, Nowell, Piansay‐Soriano, Miriam Emily , Sulyman, Omotara , Szeimies, Rolf‐Markus , Tanzi, Elizabeth L., Taub, Amy Forman , Taylor, Mark B., Thomas, J. Regan, Torezan, Luis, Tosti, Antonella, Touma, Dany, Almeida, Ada Regina Trindade de , Vedamurthy, Maya , Viana, Giovanni, Waldman, Abigail, Weinkle, Susan, Weiss, Robert, Poon, Emily, Cartee, Todd V. , Sobanko, Joseph F. , Eisen, Daniel B. , Ahmed, Areeba , Schlessinger, Daniel Isaac , Lazaro-Camp, Vanessa J, Christensen, Rachel E. , Ibrahim, Sarah A. , Cotseones, J.K., Umar, Sheikh Ahmad , Furlan, Karina Colossi , Alexiades, Macrene , Alhusayen, Raed , Beer, Kenneth Robert, Briceño, César Augusto , Bucay, Vivian , Casabona, Gabriela , Cotofana, Sebastian , Desai, Shraddha , Dover, Jeffrey S. , Draelos, Zoe Diana , Eisen, Daniel B., El-Domyati, Moetaz M. , El-Garem, Yehia, Fitzgerald, Rebecca, Friedmann, Daniel P. , Galadari, Hassan , Gladstone, Hayes B., Goldman, Mitchel P. , Goodman, Greg , Green, Jeremy B. , Halachmi, Shlomit , Humphrey, Shannon , Jagdeo, Jared R. , Jiang, Shang I. Brian , Kauvar, Arielle N.B. , Kibbi, Abdul‐Ghani , Kim, John V. S., LASK, GARY P., Matarasso, Seth L., Narins, Rhoda S., Ogilvie, Patricia , Osaki, Tammy H. , Pacheco, Theresa , Polder, Kristel D., Saedi, Nazanin, Shenoy, Manjunath , Sinclair, Rod, Solish, Nowell , Torezan, Luís , Tosti, Antonellá , Waldman, Abigail , Weiss, Robert, Maher, Ian A. , Kirkham, Jamie J

Mayo Clinic

JAMA Dermatology | June 17, 2026 | Volume: 162 | Issue: 8 | Pages: 829

10.1001/jamadermatol.2026.1697 | PMID 42307924 Get It

Importance Currently, there are no standardized outcome domains or measures in clinical trials for facial aging. Heterogeneity in outcome domains and measurement instruments across clinical trials creates difficulty in directly comparing interventions, determining superior therapies, and developing high-quality meta-analyses. Objective To develop a core outcome set (COS) of essential domains to be reported in clinical trials evaluating the efficacy of interventions for facial aging. Evidence Review PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials, and CINAHL were searched from September 2005 to September 2015. An updated search of the same databases was performed from September 2015 to February 2026. Studies were included if (1) they were randomized clinical trial or controlled clinical trial in design, (2) they assessed the efficacy or safety of an intervention for facial aging, (3) they were published in English, and (4) they involved human participants. Complementary sources, including patient interviews, were used to capture further relevant outcomes. Two rounds of Delphi surveys, followed by consensus meetings, were used to identify outcome domains considered most important by both patient and physician stakeholders. Findings The final COS consists of 6 outcome domains: (1) overall convenience of treatment; (2) time to return to normal work and social activity; (3) overall assessment of focused area of treatment (at the point in time when treatment is expected to provide peak benefit); (4) duration of treatment effect; (5) severity of persistent local or systemic adverse events, including pigmentary change, skin texture change, delayed healing, scarring, and serious adverse events; and (6) patient satisfaction with treatment. Conclusions and Relevance The 6 outcome domains identified through a Delphi consensus are recommended for reporting in future facial aging trials to ensure that outcomes that matter most to patients and clinicians are measured and that results are comparable across interventions.
Association of Glucagon-like Peptide-1 Receptor Agonist Use with Stroke and Mortality Outcomes in Asymptomatic Intracranial Atherosclerotic Disease: Propensity Score-Matched Real-World Analysis
Rai, Pranjal , Mandel, Daniel, Dhaduk, Vidhi, Rajeev, Radhika , Kakadiya, Jay , Chen, Huanwen Alvin, Salim, Hamza A., Azzam, Ahmed Y., Essibayi, Muhammed Amir, Connolly, Brian, Buzzelli, Marc, Yedavalli, Vivek S., Khan, M S, Dmytriw, Adam A. , Altschul, David J., McIntyre, Matthew K. , Colasurdo, Marco, Malhotra, Ajay , Gandhi, Dheeraj, Lakhani, Dhairya A. , Yedavalli, Vivek , Khan, Majid , Kakadiya, Jay , Dhaduk, Vidhi , Rajeev, Radhika , Azzam, Ahmed Y , Buzzelli, Marc , Yedavalli, Vivek S , Dmytriw, Adam A , McIntyre, Matthew K , Malhotra, Ajay , Rai, Pranjal , Lakhani, Dhairya , Khan, Majid , Mandel, Daniel, Bathla, Girish , Essibayi, Muhammed Amir , Altschul, David , Colasurdo, Marco , Gandhi, Dheeraj

Mayo Clinic

Neurology International | May 27, 2026 | Volume: 18 | Issue: 5 | Pages: 98

10.3390/neurolint18050098 | PMID 42188698 Get It

Background: Asymptomatic intracranial atherosclerotic arterial stenosis (ICAS) is an underrecognized entity for which vascular risk-factor optimization is the primary management strategy, with no current indication for routine antiplatelet therapy or endovascular intervention for primary stroke prevention. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events, including stroke, in high-risk cardiometabolic populations, but their association with outcomes in asymptomatic ICAS is yet to be evaluated. The present study aims to evaluate the association between GLP-1RA use and cerebrovascular outcomes in adults with asymptomatic ICAS. Materials and Methods: We used the TriNetX US Collaborative Network (71 healthcare organizations) to identify adults (≥18 years) with ICAS between 1 January 2016 and 31 December 2025, and excluded patients with prior cerebral infarction, intracranial hemorrhage, or cerebrovascular ischemic syndromes. Exposure was defined as initiation of any GLP-1 receptor agonist (lixisenatide, semaglutide, liraglutide, tirzepatide, dulaglutide) during the 6 months before or on the date of index ICAS diagnosis. Outcomes were assessed at 1 year, and included ischemic stroke, all-cause mortality, and a composite of ischemic stroke or mortality. Propensity-score matching (1:1) was performed, including demographics, vascular risk factors, comorbidities, antithrombotics, lipid/diabetes therapies, and cardiometabolic laboratory/physiologic measures. Results: Before matching, 1746 GLP-1RA users and 71,792 non-users met inclusion criteria; after matching, 1728 patients remained in each cohort. GLP-1RA use was associated with lower 1-year risk of ischemic stroke (4.40% vs. 6.10%; hazard ratio [HR] 0.70, 95% CI 0.52–0.95; p = 0.044), lower all-cause mortality (3.40% vs. 9.40%; HR 0.35, 95% CI 0.26–0.47; p < 0.001), and lower composite outcome risk (7.50% vs. 15.00%; HR 0.48, 95% CI 0.39–0.59; p < 0.001). Notably, these associations were observed despite matching for HbA1c, LDL cholesterol, BMI, and systolic blood pressure, suggesting potential effects beyond measured cardiometabolic risk profiles. Conclusions: In this large, propensity-matched cohort of adults with a-ICAS, GLP-1RA use was associated with lower ischemic stroke, all-cause mortality, and composite outcome at 1 year. These findings are hypothesis-generating and require further prospective studies to confirm this observation.
A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection
Concepcion, Beatrice P. , Bestard, Oriol, Samaniego, Milagros , Prashar, Rohini , Ansari, M. Javeed , Comai, Giorgia , Gessaroli, Elisa , Rostaing, Lionel, Alberici, Federico , Mannon, Roslyn B. , Augustine, Joshua J. , Wee, Alvin , Poggio, Emilio, DiCocco, Pierpaolo , Shawar, Saed , Maluf, Daniel, Rothstein, David M. , Cherukuri, Aravind, Connolly, Patricia, Rose, Angela, Doshi, Nehal, Gallon, Lorenzo , Donovan, Michael , Bestard, Oriol , Bestard, Oriol , Samaniego-Picota, Milagros , Rostaing, Lionel , Augustine, Joshua , Poggio, Emilio , Leca, Nicolae , Shawar, Saed , Bhati, Chandra , Rothstein, David M , Cherukuri, Aravind , Chang, Anthony , Salem, Fadi E , Kattan, Michael W , Schold, Jesse D , Connolly, Patricia , Doshi, Nehal , Gallon, Lorenzo , Mannon, Roslyn B , Ansari, Mohammed Javeed , Comai, Giorgia , Poggio, Emilio D. , Maluf, Daniel G. , Kattan, Michael W. , Donovan, Michael Joseph

Mayo Clinic

Kidney360 | May 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.34067/kid.0000001208 | PMID 42133442 Get It

Background: Although donor and recipient characteristics are used to estimate graft failure risk, they remain limited in predicting early acute rejection. We developed and validated a next-generation sequencing (NGS) assay targeting the pre-transplant immunologic profile to predict early acute rejection following kidney transplantation. Methods: This prospective, international study enrolled 321 kidney transplant participants across 13 sites, forming discovery and validation cohorts. Peripheral blood was collected prior to transplant and at 1, 3, 6, 12, and 24 months post-transplant, with protocol biopsies performed at 3 and 12 months, as well as any indication biopsies. Biopsies were assessed by a blinded central pathologist according to the 2019 Banff criteria. The pre-transplant risk assessment (PTRA™) test to evaluate RNA expression of a 29-gene signature algorithm designed to predict early acute rejection risk was clinically validated utilizing 122 deceased donor kidney transplant recipients. Results: PTRA classified 31 of 122 participants (25%) as high-risk and 91 (75%) as low-risk. There were 9 early acute rejection events in the first 60 days post-transplant: 6/31 (19%) in the high-risk group and 3/91 (3%) in the low-risk group. PTRA discrimination for early acute rejection at 60 days post-transplant yielded an AUC of 0.78 (95% confidence interval [CI]: 64.4 to 91.5), p<0.001. A cut-off of ≤45 was defined as low-risk and >45 as high-risk for early acute rejection within 60 days post-transplant. Sensitivity 0.67 (95% CI: 0.36 to 0.97), specificity 0.78 (95% CI: 0.70 to 0.86), positive predictive value 0.19 (95% CI: 0.05 to 0.33), and negative predictive value 0.97 (95% CI: 0.93 to 1.00). The odds ratio comparing patients identified as high- vs low-risk by PTRA was 7.04 (95% CI: 1.64 to 30.2), p=0.009. Conclusions: This study validates the ability of PTRA to stratify kidney transplant recipients as high- or low-risk for early acute rejection using a pre-transplant transcriptomic profile, with implications for graft health and personalized treatment management.
At‐home visual acuity in children using a custom iPhone application compared with standardized in‐office visual acuity testing
Roberts, Tawna L. , Bothun, Erick D. , Zhu, Yufeng, Henderson, Robert J. , Boyle, Nicole M, Leske, David A. , Wernimont, Suzanne M., Marino, Carrie E, Manh, Vivian M. , Youngerman, Jillian M, Qayum, Jennifer N, Srinivasan, Gayathri , Titelbaum, Jenna R. , Crouch, Eric R. , Colburn, Jeffrey, Esposito, Christina , Zeto, V Lori, Connolly, Katie, Bhakta, Rita M, Lorenzana, Ingryd J., McDowell, Paula, Beaulieu, Wesley T, Kraker, Raymond T, Holmes, Jonathan M, Pineles, Stacy L., Weise, Katherine K., Cotter, Susan A, Group, Pediatric Eye Disease Investigator, Beaulieu, Wesley T , Kraker, Raymond T , Hatt, Sarah R. , Raghuram, Aparna , McDowell, Paula S., Kraker, Raymond T. , Holmes, Jonathan M. , Cotter, Susan A.

Mayo Clinic

Optometry and Vision Science | May 1, 2026 | Volume: 103 | Issue: 4 | Pages: No page available

10.1002/ovs2.70040 | PMID 42062237 Get It

ABSTRACT Purpose To validate a custom smartphone application for at‐home visual acuity (VA) measurement in children. Methods A total of 452 children aged 3–17.5 years participated. Certified examiners measured in‐office test–retest VA (logMAR) using gold‐standard Amblyopia Treatment Study HOTV (3‐to‐6‐year‐olds, younger cohort) or electronic Early Treatment of Diabetic Retinopathy Study (7‐to‐17.5‐year‐olds, older cohort) protocols at 3–4.5 m and app‐based VA at 1.5 m. Caregivers measured at‐home app‐based VA at 1.5 m. Results Comparing at‐home app‐based with gold‐standard VA, in eyes 20/40 or better, 95% (143/151) and 93% (91/98) of the younger and older cohorts were within 2 lines, respectively (mean differences: younger = −0.03, older = −0.04; 95% limits‐of‐agreement half‐width (LOA): younger = ±0.26, older = ±0.22). In eyes 20/50 or worse, 66% (42/64) and 75% (76/101) of the younger and older cohorts were within 2 lines, respectively (mean differences: younger = 0.11, older = 0.13, LOA: younger = ±0.50, older = ±0.51). Comparing in‐office app‐based VA with gold‐standard VA, in eyes 20/40 or better, 98% (160/164) and 94% (99/105) of the younger and older cohorts were within 2 lines, respectively (mean differences: younger = −0.03, older = −0.03; LOA: younger = ±0.22; older = ±0.24). In eyes 20/50 or worse, 85% (60/71) and 91% (101/111) of the younger and older cohorts were within 2 lines, respectively (mean differences: younger = 0.04; older = 0.04; LOA: younger = ±0.39; older = ±0.24). For gold‐standard test–retest, in eyes 20/40 or better, 99% (163/164) and 99% (104/105) of the younger and older cohorts had retest within 2 lines, respectively (mean differences: younger = 0.00; older = 0.01; LOA: younger = ±0.17; older = ±0.11). For 20/50 or worse, 92% (66/72) and 100% (111/111) in the younger and older cohorts were within 2 lines, respectively (mean differences: younger = 0.01; older = 0.02; LOA: younger = ±0.35; older = ±0.15). Conclusions Our app demonstrated good concordance with the gold standard at home and in the office for eyes with VA of 20/40 or better. However, concordance decreased considerably for eyes with VA 20/50 or worse, particularly at home.